108 completed, 11 recruiting, 8 unknown, 7 terminated. 49 Phase 3, 27 Phase 4, 16 Phase 1, 15 Phase 2, 5 Not applicable.
Follow Factor VIII: new trials by email Literature Review of Factor VIII trials Research Report on Factor VIII
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Post Approval Phase 4 Study to Learn More About How Safe Octocog Alfa is, and How Well it Works in Patients With Severe Hemophilia A in India Octocog alfa - Severe Hemophilia A | Not yet recruiting | Bayer | 30 | 2027-04-05 | 2026-10-21 | |
| Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational Study efmoroctocog alfa - Hemophilia A, Hemophilia | Not yet recruiting | AryoGen Pharmed Co. | 262 | 2026-08-23 | 2026-08-28 | |
| An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia A Damoctocog alfa pegol (Jivi, Bay94-9027) - Hemophilia A | Not yet recruiting | Bayer | 40 | 2026-06-30 | 2026-06-26 | |
| A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A NXT007, Human Coagulation Factor VIII - Hemophilia A | Phase 3 | Recruiting | Hoffmann-La Roche | 138 | 2026-05-15 | 2026-09-23 |
| Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery Nuwiq - Hemophilia A | Phase 4 | Recruiting | Octapharma | 28 | 2026-04-01 | 2026-05-12 |
| A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD) VONVENDI, ADVATE - Von Willebrand Disease (VWD) | Phase 3 | Recruiting | Takeda | 20 | 2025-10-13 | 2026-01-08 |
| A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea OBIZUR - Acquired Hemophilia A | Recruiting | Takeda | 9 | 2025-07-22 | 2026-09-11 | |
| A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates - Von Willebrand Disease, Type 3 | Phase 3 | Recruiting | Hoffmann-La Roche | 75 | 2025-06-27 | 2026-10-09 |
| Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients Emicizumab Injection, Factor VIII (FVIII) - Hemophilia A | Phase 2 / Phase 3 | Not yet recruiting | Dhaka Medical College | 20 | 2025-06-01 | 2025-04-22 |
| Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study) Advate® - Hemophilia a with Inhibitor | Phase 4 | Recruiting | Runhui WU | 110 | 2025-03-01 | 2025-03-07 |
| A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD) Vonicog Alfa, ADVATE - Von Willebrand Disease (VWD) | Phase 3 | Recruiting | Takeda | 24 | 2024-11-06 | 2026-09-09 |
| A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients With VWD Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII, Placebo - Von Willebrand Diseases | Phase 3 | Recruiting | Unity Health Toronto | 20 | 2024-10-21 | 2026-10-14 |
| A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A Damoctocog-alfa-pegol (Jivi, BAY94-9027) - Hemophilia A, Prophylaxis of Bleeding | Recruiting | Bayer | 20 | 2024-01-24 | 2026-06-22 | |
| Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study Nuwiq - Severe Hemophilia A | Phase 4 | Recruiting | Octapharma | 28 | 2023-11-28 | 2026-05-12 |
| rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study Factor VIII, recombinant human with Fc fusion (rFVIII-Fc) - Severe Hemophilia A | Phase 3 | Completed | AryoGen Pharmed Co. | 50 | 2023-07-22 | 2023-11-18 |
| A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A Adynovate - Hemophilia A | Phase 3 | Completed | Takeda | 37 | 2023-03-27 | 2025-05-01 |
| An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A. Damoctocog alfa pegol (Jivi, BAY94-9027) - Hemophilia A, Prophylaxis of Bleeding | Active not recruiting | Bayer | 33 | 2022-12-29 | 2026-07-01 | |
| Prophylaxis Regimen for Hemophilia A Patients Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG). - Hemophilia A, Prophylaxis of Bleeding | Phase 4 | Completed | Bayer | 21 | 2022-07-28 | 2025-11-12 |
| A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood Damoctocog alfa pegol (Jivi, BAY94-9027) - Treatment of Bleeding, Prophylaxis of Bleeding | Phase 3 | Completed | Bayer | 36 | 2022-03-23 | 2026-07-02 |
| Emicizumab PUPs and Nuwiq ITI Study Nuwiq (low dose protocol), HEMLIBRA, Nuwiq (Atlanta protocol) - Hemophilia A | Phase 3 | Withdrawn | Emory University | 2022-02-17 | 2024-01-05 |
Showing 20 of 146. Sign in to see all of them.
Hemophilia A (125) · von Willebrand Diseases (11) · Blood Coagulation Disorders (5) · Factor 8 deficiency, acquired (4) · Hematologic Diseases (4) · Hemophilia B (2) · Joint Diseases (2) · Motor Activity (2) · Blood Platelet Disorders (1) · Bone Diseases (1) · Coagulation Protein Disorders (1) · Genetic Diseases, Inborn (1) · Hemarthrosis (1) · Hemorrhage (1) · Hemorrhagic Disorders (1)
Bayer (38) · Baxalta now part of Shire (28) · Pfizer (7) · Takeda (7) · Octapharma (6) · Bio Products Laboratory (5) · CSL Behring (5) · Hoffmann-La Roche (4) · Wyeth is now a wholly owned subsidiary of Pfizer (4) · Bioverativ Therapeutics Inc. (3) · Bioverativ, a Sanofi company (3) · Novo Nordisk A/S (3) · AryoGen Pharmed Co. (2) · City of Hope Medical Center (2) · Emory University (2)
United States (62) · Italy (44) · Spain (39) · Germany (38) · United Kingdom (34) · Poland (26) · Bulgaria (25) · Canada (25) · France (24) · Netherlands (24) · Austria (22) · Russia (19) · Japan (18) · China (17) · Belgium (15)
Renchi Yang, PhD (2) · Akhil R. Biswas, MBBS, FCPS (1) · Anne-Mette Hvas, MD, Ph.D. (1) · Aziz Eghbali, Assoc. Prof. (1) · Brian Feldman, MD,MSc,FRCPC (1) · Brian M Feldman, MD (1) · Christopher Denton, PhD (1)
PMID 19216617, PMID 26931631, PMID 26157075, PMID 27002680, PMID 17938794, PMID 21443634, PMID 22212248, PMID 23528101, PMID 23750875, PMID 24227821, PMID 24843882, PMID 25196897, PMID 25495795, PMID 25546368, PMID 25855376, PMID 25912619, PMID 25952661, PMID 26239086, PMID 26663410, PMID 27223147, PMID 27328112, PMID 27330001, PMID 27339736, PMID 27436242, PMID 27577234, PMID 27891721, PMID 28005225, PMID 28220555, PMID 28768627, PMID 28836341, PMID 29296836, PMID 29575770, PMID 29731369, PMID 30013766, PMID 30157389, PMID 31152037, PMID 31236667, PMID 31697801, PMID 31778283, PMID 32197139, PMID 32905674, PMID 32974838, PMID 33269010, PMID 33719084, PMID 33724632, PMID 34475142, PMID 34589194, PMID 34855619, PMID 35421219, PMID 35439298
2008 (8), 2014 (5), 2023 (4), 2009 (3), 2015 (3), 2016 (3), 2018 (3), 2017 (2), 2025 (1), R34HL105870 (1)